Compare Moderna, Inc. (MRNA) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs UnitedHealth Group Inc — how do they compare? Moderna, Inc. trades at $137.44 (market cap $56.02B), while UnitedHealth Group Inc trades at $394.32 (market cap $359.79B). The key difference: UnitedHealth Group Inc is far larger — about 6.4× Moderna, Inc.'s market cap, and UnitedHealth Group Inc pays a 2.32% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | UNH | |
|---|---|---|
Market Cap | $56.02B | $359.79B |
Sector | Health | Health |
52-Week High | $174.38 | $436.35 |
52-Week Low | $22.36 | $259.02 |
Enterprise Value | $52.17B | $401.65B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
UnitedHealth Group (UNH) trades at $393.06, down 1.03% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $447.57B in 2025, with net income of $12.06B, and has beaten EPS estimates in recent quarters. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
The outlook for UNH is positive, driven by aging demographics, Medicare growth, and operational efficiencies, though risks include regulatory scrutiny and margin pressures. With 82.7% of analysts rating it a buy and a consensus price target of $475.47, the stock presents a compelling opportunity for long-term investors seeking exposure to healthcare stability and dividend growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
